Breathing Gases Patents (Class 514/959)
-
Patent number: 9023402Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.Type: GrantFiled: April 1, 2011Date of Patent: May 5, 2015Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
-
Patent number: 8323680Abstract: A nutritional or therapeutic composition for oral administration which comprises a naturally occurring precursor that is metabolised to a compound having anandamide activity for use as a medicament or nutritive product. In addition the invention includes a method of production of the composition, use of the composition in the manufacture of a nutritional composition for the treatment or prevention of a behavioral disorder; and a method of treatment or prevention of a behavioral disorder which comprises administering an effective amount of the composition. In a preferred embodiment the composition comprises a triacylglycerol having palmitate and arachidonate attached to its backbone wherein arachidonate is at the sn-1 and sn-2 positions.Type: GrantFiled: September 14, 2000Date of Patent: December 4, 2012Assignee: Nestec S.A.Inventors: Alvin Berger, Gayle Crozier
-
Patent number: 8236348Abstract: Flavored dosage forms, e.g., lozenges and gums, are provided for sustained release of a flavoring agent in the mouth. The dosage forms provide sustained release by virtue of a wet matrix formed by admixture of a biocompatible, hydrophilic, water-insoluble polymer such as ethylcellulose and a flavoring agent, particularly an essential oil or a constituent thereof, e.g., a terpene or sesquiterpene. The dosage forms may also include a second beneficial agent in addition to the flavoring agent. Exemplary such beneficial agents include ionizable zinc compounds and other cold remedies, local anesthetic and anti-infective agents, diet aids, fluoride-releasing compounds, and nicotine. The dosage forms, when formulated as lozenges, may be somewhat adhesive or substantially nontacky, depending primarily on the molecular weight of the hydrophilic polymer. Adhesive lozenges can serve as dosage forms that adhere to the teeth or gums for delivery of a beneficial agent thereto.Type: GrantFiled: February 4, 2004Date of Patent: August 7, 2012Assignee: Bennes, Inc.Inventors: Jerry B. Gin, Benjamin F. Ross
-
Patent number: 7754763Abstract: An oral spray composition for preventing and/or reducing the symptoms of the common cold including a zinc formulation containing both zinc acetate and zinc gluconate to ensure sustained availability of increased amounts of ionizable zinc.Type: GrantFiled: April 30, 2004Date of Patent: July 13, 2010Assignee: Zicam, LLCInventor: Tim Clarot
-
Patent number: 7632872Abstract: In a first aspect, the present invention relates to the use of xenon in the preparation of a medicament for providing analgesia in a newborn subject and/or a fetal subject. In a second aspect, the invention relates to a method of providing analgesia in a newborn subject, the method comprising administering to the subject a therapeutically effective amount of xenon. In a third aspect, the invention relates to a method of providing analgesia in a fetal subject, the method comprising administering to the mother of the fetal subject a therapeutically effective amount of xenon for both the mother and fetal subject.Type: GrantFiled: August 5, 2003Date of Patent: December 15, 2009Assignee: Protexeon LimitedInventors: Nicholas Peter Franks, Mervyn Maze
-
Patent number: 7566704Abstract: The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble ?-glucan composition comprising ?-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).Type: GrantFiled: January 17, 2006Date of Patent: July 28, 2009Assignee: Biopolymer Engineering, Inc.Inventors: Myra L. Patchen, Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 7390508Abstract: The present invention relates to the use of xenon in the preparation of a medicament for the treatment of neonatal asphyxia in a neonatal subject, wherein said medicament is for use in combination with hypothermia.Type: GrantFiled: October 11, 2004Date of Patent: June 24, 2008Assignee: Protexeon LimitedInventors: Nicholas Peter Franks, Mervyn Maze
-
Patent number: 7279457Abstract: Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration. In the preferred embodiments, the formulations are administered sublingually or via subcutaneous injection. The formulations contain an active agent and one or more excipients, selected to increase the rate of dissolution. In the preferred embodiment, the drug is insulin, and the excipients include a metal chelator such as EDTA and an acid such as citric acid. Following administration, these formulations are rapidly absorbed by the oral mucosa when administered sublingually and are rapidly absorbed into the blood stream when administered by subcutaneous injection. In one embodiment, the composition is in the form of a dry powder.Type: GrantFiled: March 11, 2005Date of Patent: October 9, 2007Assignee: Biodel, Inc.Inventors: Roderike Pohl, Solomon S. Steiner
-
Patent number: 7235264Abstract: Xenon or xenon-containing gases and, where appropriate, an NO source are employed as medicament for cerebral protection. Cerebral protection is defined as reducing or preventing impairments of cerebral function of various causes, but especially secondary to perfusion impairments of unclear etiology. The medicament can be used for cerebral protection for the prophylaxis of impairments of cerebral perfusion and for therapy after cerebral disorders have occurred, irrespective of the cause (e.g. cognitive, sensory or motor in nature).Type: GrantFiled: June 12, 2003Date of Patent: June 26, 2007Assignee: Air Liquide Deutschland GmbHInventors: Peter Neu, Carsten Pilger, Matthias Reyle-Hahn
-
Patent number: 7045152Abstract: Pulmonary disorders in which the GSNO pool or glutathione pool in the lung is depleted and where reactive oxygen species in lung are increased, are treated by delivering into the lung as a gas, agent causing repletion or increase of the GSNO pool or protection against toxicity and does so independently of reaction with oxygen. Agents include ethyl nitrite, NOCl, NOBr, NOF, NOCN, N2O3, HNO, and H2S. Optionally, N-acetylcysteine, ascorbate, H2S or HNO is administered in addition to other GSNO repleting agent to potentiate the effect of said agent.Type: GrantFiled: February 14, 2001Date of Patent: May 16, 2006Assignee: Duke UniversityInventor: Jonathan S. Stamler
-
Patent number: 7029656Abstract: Formulations, methods and devices for producing formulations and methods for nebulizer delivery of formulations of water-insoluble drugs are provided. Also provided are methods for minimizing wastage of drugs administered by nebulizer, and for the achievement of quantitative dosing with diluent from a mass marketed formulations, which because of the mass market is much less costly per dose than formulations manufactured specifically for much lower volume medical use.Type: GrantFiled: December 15, 2000Date of Patent: April 18, 2006Inventor: Robert E. Coifman
-
Patent number: 7022685Abstract: The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble ?-glucan composition comprising ?-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).Type: GrantFiled: March 7, 2002Date of Patent: April 4, 2006Assignee: Biopolymer Engineering, Inc.Inventors: Myra L. Patchen, Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 7011854Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.Type: GrantFiled: February 3, 2003Date of Patent: March 14, 2006Assignee: Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos LdaInventors: Werner Haas, Carlos Romao, Beatriz Roya, Ana Cristina Fernandes, Isabel Goncalves
-
Patent number: 6680284Abstract: For the preparation of pulverulent particle-reduced formulations with the aid of compressed gases, the solid compound to be formulated, a poorly soluble and usually bioactive active compound, is homogeneously ground together with 10-99% by weight (based on the formulation) of a carrier material which is essentially soluble in the compressed gas mixture, in the presence of compressed gas or mixtures thereof in a stirred autoclave having a mechanical grinding device at process temperatures between 10 and 200° C. and at process pressures between 5 and 500 bar, and in a second process stage the compressed gas mixture, usually dimethyl ether, pure propane and/or carbon dioxide, is expanded by lowering the pressure and separated off from the homogenate, which can also be present as a melt.Type: GrantFiled: January 3, 2002Date of Patent: January 20, 2004Assignee: Degussa AGInventors: Jürgen Heidlas, Martin Ober, Johann Wiesmüller
-
Patent number: 6653354Abstract: The present invention relates to the use of xenon as a neuroprotectant and/or as an inhibitor of synaptic plasticity. In a preferred aspect, the xenon acts as an NMDA antagonist. The present invention also provides a method of reducing the level of activation of the NMDA receptors in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon, wherein said reduction achieves neuroprotection and/or an inhibition of synaptic plasticity. A further embodiment of the invention provides a pharmaceutical composition for providing neuroprotection and/or inhibition of synaptic plasticity, together with a process for the preparation thereof.Type: GrantFiled: June 14, 2001Date of Patent: November 25, 2003Assignee: Protexeon LimitedInventors: Nicholas Peter Franks, Mervyn Maze
-
Patent number: 6558618Abstract: A method of dispersing, in water vapor, an anti-infective therapeutic composition (10) into the air in a room (36), in order to treat or prevent transmission of upper respiratory infections, includes: adding to a reservoir of liquid water in a vaporizer (34), a therapeutic composition (10) containing one or more antibiotics (14), alcohol (16), an analgesic (18) and an expectorant (20); and vaporizing the therapeutic composition (10) into the air along with the water in the vaporizer reservoir for inhalation by persons in the room.Type: GrantFiled: April 27, 1999Date of Patent: May 6, 2003Inventor: James L Dent, Jr.
-
Patent number: 6482391Abstract: A method and apparatus is disclosed for treating asthma and other respiratory conditions. A medicament comprising a surface active phospholipid (SAPL) is prepared in the form of a fine powder and administered to the lungs in a gas stream. A preferred SAPL is a solid blend of dipalmitoyl phosphatidyl choline (DPPC) and phosphatidyl glycerol (PG).Type: GrantFiled: August 10, 2000Date of Patent: November 19, 2002Assignee: Britannia Pharmaceuticals LimitedInventors: Brain Andrew Hills, Derek Alan Woodcock
-
Patent number: 6369216Abstract: The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble &bgr;-glucan composition comprising &bgr;-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).Type: GrantFiled: June 3, 1999Date of Patent: April 9, 2002Assignee: Biopolymer Engineering Pharmaceutical, Inc.Inventors: Myra L. Patchen, Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
-
Patent number: 6365209Abstract: A novel encapsulated product is provided and includes: at least one active ingredient; at least one compressible material; and at least one tableting material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A method for preparing the encapsulated product is also provided. The encapsulated product may be incorporated into a food item, a soft confectionery product, a hard confectionery product, a jelly gum confectionery product, and a dry beverage or chewing gum product.Type: GrantFiled: February 7, 2001Date of Patent: April 2, 2002Assignee: Capricorn Pharma, Inc.Inventor: Subraman Rao Cherukuri
-
Patent number: 6362225Abstract: Therapies and compositions are described for use in the treatment of a variety of common viral infections such as those of the upper respiratory tract, eye, stomach and intestines, and such viral lesions as cold sores, canker sores and those caused by genital herpes. The effective ingredient in the various therapies and compositions is the compound L-Lysine monohydrochloride (lysine). The crystalline lysine is ground into a fine powder and dispersed in a variety of aqueous media and other carrier systems. A solution in the form of a spray is administered to the nasal membranes, the mouth and throat, and to the lungs. Lozenges are designed to be dissolved in the mouth, both above the tongue and sublingually, and gels and solutions are applied directly to the lesions. Lysine is also administered in the form of drops, chewing gum, suppositories and by enema. In microcrystalline powder form the lysine may be administered directly into the lungs.Type: GrantFiled: January 6, 2000Date of Patent: March 26, 2002Inventor: George Andreakos
-
Patent number: 6333057Abstract: This invention relates to the topical and oral treatment of hair loss, especially androgenic alopecia, by providing formulations that include anti-androgens, especially extracts of the saw palmetto plant, co-enzyme Q, and acetyl carnitine, and optionally stimulators of adenylate cyclase to stimulate hair growth, to increase the luster of hair, and to decrease hair graying.Type: GrantFiled: July 16, 1998Date of Patent: December 25, 2001Inventor: Wilson T. Crandall
-
Patent number: 6303156Abstract: The present invention is directed to a method for changing the body temperature of a patient by having them hyperventilate a gas mixture containing sulfur hexafluoride and oxygen. The method may be applied to cool patients in any clinical situation where induced hypothermia is desirable or to rapidly rewarm hypothermic patients. The invention also includes the gas mixtures used in the method.Type: GrantFiled: June 22, 1999Date of Patent: October 16, 2001Assignee: The Brigham and Women's Hospital Inc.Inventor: Massimo Ferrigno
-
Patent number: 6274633Abstract: The present invention relates to the use of xenon as an NMDA antagonist. In particular, the invention relates to a method of treatment comprising modulating the activity of an NMDA receptor in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon. In a further aspect, the invention provides a process for the preparation of a pharmaceutical composition suitable for modulating the activity of an NMDA receptor.Type: GrantFiled: August 23, 1999Date of Patent: August 14, 2001Assignee: Imperial College of Science, Technology, and MedicineInventors: Nicholas Peter Franks, Mervyn Maze
-
Patent number: 6174873Abstract: Disclosed are compositions including an adenosine analog, wherein the composition comprises a dosage form suitable for oral (co)administration. Also disclosed are compositions including adenosine analogs, wherein the composition is in a dosage form including a pill, capsule, lozenge, or tablet, and compositions including adenosine analogs, wherein the composition is in a dosage form comprising a liquid. Additionally disclosed are methods of administering the inventive composition, and kits including the inventive compositions.Type: GrantFiled: November 4, 1998Date of Patent: January 16, 2001Assignee: SuperGen, Inc.Inventor: Simeon M. Wrenn, Jr.
-
Patent number: 6138683Abstract: A composition for inclusion within a quantity of smokeless tobacco. The composition of antioxidants is capable of reducing free radical damage to the oro-pharyngeal cavity of a user resulting from consumption of smokeless tobacco. The composition includes L-glutathione and a source of selenium.Type: GrantFiled: November 3, 1998Date of Patent: October 31, 2000Assignee: Thione International, Inc.Inventors: Ted Hersh, Rebecca Hersh
-
Patent number: 6060045Abstract: Wicks or pads for use in vitaminized air fresheners and room deodorizer devices are disclosed, which permit devices occupants to directly receive and enjoy the benefits of vitamins with little or no effort intra-nasally as they breath the released volatile compositions. A method for the continuous release of a vitamin containing composition for the delivery of discrete droplets intra nasally absorbed vitamins such as, but not limited to A, C, and D is also disclosed.Type: GrantFiled: March 16, 1999Date of Patent: May 9, 2000Inventor: Leo Mettler
-
Patent number: 6001332Abstract: A medical gas mixture which comprises from 20 to 70% oxygen, from 1 to 10% carbon dioxide and the balance, except for incidental constituents not adversely affecting the basic properties of the gas mixture, being helium. The subject mixtures are useful in the treatment of asthma and in enhancing magnetic resonance imaging.Type: GrantFiled: April 2, 1998Date of Patent: December 14, 1999Assignee: The BOC Group plcInventor: Michael E. Garrett
-
Patent number: 5891427Abstract: Vitaminized air fresheners and room deodorizers are disclosed which permit occupants to directly receive and enjoy the benefits of vitamins with little or no effort intra-nasally. A method for the continuous release of a vitamin containing composition for the delivery of discrete droplets intra nasally absorbed vitamins such as, but not limited to A, C, and D is also disclosed.Type: GrantFiled: February 28, 1998Date of Patent: April 6, 1999Inventor: Leo Mettler
-
Patent number: 5733939Abstract: A method for reducing the inflammatory response in tissues of a patient, by contacting the tissue with an effective, inflammation-reducing amount of a liquid or gaseous fluorocarbon.Type: GrantFiled: November 22, 1995Date of Patent: March 31, 1998Assignee: Alliance Pharmaceutical Corp.Inventors: Bradley Phillip Fuhrman, Stephen F. Flaim, Lynn Joanne Hernan, Frances Darey Nesti, Michele Cecile Papo, David Marc Steinhorn
-
Patent number: 5660835Abstract: A method of treating adenosine depletion in a subject in need of such treatment is disclosed. The method comprises administering to the subject folinic acid or a pharmaceutically acceptable salt thereof in an amount effective to treat adenosine depletion. A method of treating asthma in a subject in need of such treatment is also disclosed. The method comprises administering to the subject dehydroepiandrosterone, analogs thereof, or pharmaceutically acceptable salts thereof in an amount effective to treat asthma.Type: GrantFiled: February 24, 1995Date of Patent: August 26, 1997Assignee: East Carolina UniversityInventor: Jonathan W. Nyce
-
Patent number: 5654288Abstract: NADH and/or NADPH is applied topically to the skin. It was surprising and totally unexpected to discover that NADH and NADPH are absorbed by the skin and penetrate the cutis to be taken up by the skin cells, where they stimulate certain enzymes which are essential for the energy production of the cells. The enzymes stimulated are principally the mitochondrial enzymes. The NADH and/or NADPH can be incorporated into a skin compatible cream, lotion or cosmetic. Liposomes are ideal vesicles for carrying the NADH and/or NADPH into the skin. In other embodiments of the invention, NADH and/or NADPH is administered nasally (e.g., as a liquid spray or a powder spray through the nostrils), sublingually (e.g., in the form of uncoated tablets inserted underneath the tongue) and rectally (e.g., in the form of suppositories) for known therapeutic effects (e.g., the treatment of Parkinson's disease).Type: GrantFiled: April 10, 1996Date of Patent: August 5, 1997Assignee: Birkmayer Pharmaceuticals, Inc.Inventor: Joerg G. D. Birkmayer
-
Patent number: 5593672Abstract: A method is provided for increasing and maintaining the quantity and activity of immune leukocyte effector cells in preparation for lymphokine and cytokine administration before and during treatment for disease pathogens. The method simultaneously up-regulates the expression of high affinity IL-2 receptors on the above mentioned cells, making them receptive to subsequent IL-2 administration, which activates and directs these cells to mediate cytotoxic activity against disease pathogens. The method may also be employed in conjunction with the administration of other lymphokines, cytokines, biological response modifiers and pharmacological compounds whose activity would benefit from an increase in effector cells. The preferred method of administration is by inhalation of a zinc oxide fume or particulate from 15 to 900 mg ZnO/m.sup.3 for one or more exposures per day, one hour or less per exposure.Type: GrantFiled: October 17, 1994Date of Patent: January 14, 1997Inventor: Robert Sabin
-
Patent number: 5525347Abstract: The invention provides a pharmaceutical composition for treating performance anxiety and social phobia comprising a therapeutic amount for the treatment of a patient of a .beta.-adrenergic receptor blocking compound and an anti-diaphoretic compound. The preferred .beta.-adrenergic receptor blocking compound is the lipophilic .beta.-blocker propranolol HCL. The anti-diaphoretic compound of the present invention is preferably glycopyrrolate. The composition for treating performance anxiety and social phobia can further include a pharmaceutically acceptable carrier. A method of preventing or treating performance anxiety or social phobia in a patient comprising administering the composition of the invention to a patient in need of such treatment is also provided. The composition administered in the present method comprises a therapeutic amount of a .beta.-adrenergic receptor blocking compound and an anti-diaphoretic compound.Type: GrantFiled: January 31, 1995Date of Patent: June 11, 1996Assignee: Medical University of South CarolinaInventors: Charles H. Kellner, Cherry W. Jackson, C. Lindsay DeVane
-
Patent number: 5470885Abstract: A method for reducing the inflammatory response in tissue of a patient, by contacting the tissue with an effective, inflammation-reducing amount of a liquid or gaseous fluorocarbon.Type: GrantFiled: September 29, 1993Date of Patent: November 28, 1995Assignee: The Research Foundation of the State University of New YorkInventors: Bradley P. Fuhrman, Stephen F. Flaim, Lynn J. Hernan, Frances D. Nesti, Michele C. Papo, David M. Steinhorn
-
Patent number: 5332727Abstract: A stable, ingestable and intestine-absorbable therapeutic composition comprising NADH or NADPH, or physiologically acceptable salts thereof, in a pill form. The pill has an outer surface covered by an acid stable protective coating. This oral form of NADH/NADPH may be taken for a variety of known therapeutic effects.Type: GrantFiled: April 29, 1993Date of Patent: July 26, 1994Assignee: Birkmayer U.S.A.Inventor: Joerg G. D. Birkmayer
-
Patent number: 5320841Abstract: Oral pharmaceutical compositions containing high content anthocyanosides, preferably higher than 80% w/w, suspended in fractionated coconut oil have higher bioavailability than water solutions or suspensions in other lipophilic carriers.Type: GrantFiled: May 3, 1993Date of Patent: June 14, 1994Assignee: IdB Holding S.p.A.Inventors: Robert Seghizzi, Bruno Gabetta, Paolo Morazzoni
-
Patent number: 5290540Abstract: A method of treating pneumonia caused by a microorganism by administering directly into the lower respiratory tract of a host an amount of an anti-inflammatory agent effective to reduce inflammation is provided. The method may further include administering to a host an amount of an anti-infectious agent with activity against the microorganism effective to reduce the concentration of the microorganism.Type: GrantFiled: May 1, 1992Date of Patent: March 1, 1994Assignee: Henry M. Jackson Foundation for the Advancement of Military MedicineInventors: Gregory A. Prince, Val G. Hemming
-
Patent number: 5130412Abstract: An electrically conducting self-doped carbazole polymer of the formula: ##STR1## wherein A is a bifunctional molecule capable of bonding to a positively charged molecule at one end and is capable of bonding to a flexible spacer group Z at another end, Z is a flexible spacer group capable of bonding to an anionic group A at one end and is capable of bonding either to a nitrogen or aromatic electron withdrawing or electron donating group at another end, E is a bifunctional molecule capable of bonding to nitrogen at one end and is capable of bonding to a flexible spacer group Z at anther end, X is a positively charged counterion, and n is at least 2.Type: GrantFiled: October 16, 1990Date of Patent: July 14, 1992Assignee: Southwest Research InstituteInventors: Stephen T. Wellinghoff, Charles K. Baker
-
Patent number: 4994441Abstract: Adhesion of bacteria in the buccal cavity which are responsible for the formation of dental plaque and caries is inhibited by kappa-caseino-glycopeptide compounds and desialylated derivaties thereof contained in compositions having a form suitable for being empolyed for treating the bacteria in the buccal cavity.Type: GrantFiled: February 8, 1988Date of Patent: February 19, 1991Assignee: Nestec S.A.Inventor: Jean-Richard Neeser
-
Patent number: 4992420Abstract: Kappa-caseino-glycopeptide compounds and desialylated derivatives thereof and compositions containing the same are employed for treating bacteria in the buccal cavity which are responsible for the formation of dental plaque and caries.Type: GrantFiled: July 17, 1990Date of Patent: February 12, 1991Assignee: Nestec S.A.Inventor: Jean-Richard Neeser
-
Patent number: 4895719Abstract: A system and method for administering a drug, at a selected dose, via the respiratory tract. Spray-dried liposome particles containing the selected dose of the entrapped drug are released into the air in aerosolized form, either by entrainment in an air or propellant stream, or by release from a pressurized can containing a suspension of the liposomes in a fluorchlorocarbon solvent.Type: GrantFiled: March 6, 1987Date of Patent: January 23, 1990Assignee: Liposome Technology, Inc.Inventors: Ramachandran Radhakrishnan, Paul J. Mihalko, Robert M. Abra
-
Patent number: 4832994Abstract: Anti-smoking oral preparations are provided containing a silver compound as the anti-smoking agent and a sweetener in which the silver compound is present in amounts of from 0.1 mg. to 2.5 mg. and the ratio of sweetness intensity based on sucrose to silver compound content is from 100:1 to 2500:1.Type: GrantFiled: September 2, 1987Date of Patent: May 23, 1989Inventor: Michael S. Fey
-
Patent number: 4803066Abstract: Pharmaceutical compositions which are suitable for topical application in the treatment of bacterial and/or fungal infections are described. The compositions comprise a synergistic mixture of a silver compound and an azole derivative together with a pharmaceutically acceptable carrier therefor. The compositions may be applied topically in the treatment of burns ulcers and other skin lesions, general skin infections and also in the treatment of infections of the mucous membranes. Preferred compositions contain silver sulphadiazine and clotrimazole or metronidazole. The compositions may be applied as ointments, gels, pessaries, tablets and the like.Type: GrantFiled: March 19, 1987Date of Patent: February 7, 1989Assignee: Smith & Nephew Associated Companies p.l.c.Inventor: Linda M. Edwards
-
Patent number: 4794000Abstract: The present invention provides for an oral drug delivery system based on a two phase liquid coacervate system prepared from water and one or more surfactants selected from anionic, cationic, amphoteric, and non-toxic surfactants, polysaccharides, synthetic polymers and polysorbates and their derivatives, and in which a pharmaceutical component is incorporated. The delivery system may be prepared in the form of a microemulsion as well as other forms including encapuslated microparticles. The claimed oral composition is useful to delivery oral dosage forms of drugs, their salts and derivatives thereof; biologicals, enzymes, and other pharmocologically active compositions. A method to prepare the oral drug delivery system is also disclosed.Type: GrantFiled: January 8, 1987Date of Patent: December 27, 1988Assignee: Synthetic Blood CorporationInventor: Bernard Ecanow
-
Patent number: 4650667Abstract: Gas-emitting bath additive compositions are stably preserved over a long term. They comprise a carbonate, an organic acid, and a stabilizer which is selected from magnesium oxide, sodium aluminate and a mixture thereof. Magnesium oxide and sodium aluminate are effective to improve the preservation stability of bath additives when used in an amount of 0.1 to 1.5 wt % of the total composition.Type: GrantFiled: February 7, 1984Date of Patent: March 17, 1987Assignee: Kao CorporationInventors: Yasuteru Eguchi, Hidenori Yorozu, Eiji Iijima
-
Patent number: 4626427Abstract: Preparation being effective against bad breath, particularly caused by strongly smelling food stuffs or cigarettes, alcohol and the like, consisting of cardamom seeds which are individually or jointly coated by a shell mass comprising a sugar mass or the like.Type: GrantFiled: September 16, 1985Date of Patent: December 2, 1986Assignee: Richardson-Vicks Inc.Inventors: Horst G. P. Wienecke, Karl-Wilhelm Stock
-
Patent number: 4557754Abstract: A novel compound bis-(N,N-dimethyl-N-carbodecyloxymethyl-N-ethyleneammonium)-sulphide dichloride of the formula ##STR1## A method for preparing said novel compound comprising quaternization of bis-(.beta.-dimethylaminoethyl)-sulphide with monochloroacetic acid decyl ester, molar ratio of said reagents being not more than 1:2.A chemotherapeutic antimicrobial preparation comprising said novel compound as an active principle in combination with a pharmaceutical carrier.A plant growth regulator in the form of an aqueous solution of said novel compound in a concentration of from 0.0001 to 0.1 wt. %.Type: GrantFiled: August 13, 1980Date of Patent: December 10, 1985Assignee: Institut Organicheskoi KhimiiInventors: Georgy A. Golik, Yaroslav P. Demchenko, Miron O. Lozinsky, Vladlen V. Malovik, Valery Y. Semeny
-
Patent number: RE37525Abstract: A method of treating pneumonia caused by a microorganism by administering directly into the lower respiratory tract of a host an amount of an anti-inflammatory agent effective to reduce inflammation is provided. The method may further include administering to a host an amount of an anti-infectious agent with activity against the microorganism effective to reduce the concentration of the microorganism.Type: GrantFiled: February 28, 1996Date of Patent: January 22, 2002Assignee: Henry M. Jackson FoundationInventors: Gregory A. Prince, Val G. Hemming
-
Patent number: RE38071Abstract: A method of treating pneumonia caused by a microorganism by administering directly into the lower respiratory tract of a host an amount of an anti-inflammatory agent effective to reduce inflammation is provided. The method may further include administering to a host an amount of an anti-infectious agent which activity against the microorganism effective to reduce the concentration of the microorganism.Type: GrantFiled: March 24, 2000Date of Patent: April 8, 2003Assignee: The Henry M. Jackson Foundation for the Advancement of Military MedicineInventors: Gregory A. Prince, Val G. Hemming